Ring Sulfur In The Additional Hetero Ring Patents (Class 514/342)
  • Patent number: 11021474
    Abstract: The present invention relates to the field of anti-viral active agents, particularly the free base hemihydrate form of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide as well as methods for the manufacture thereof. The present invention relates also to the use of the above compound in the treatment of human herpes virus infections and in the preparation of pharmaceuticals comprising said compound.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: June 1, 2021
    Assignee: AiCuris Anti-Infective Cures GmbH
    Inventors: Yogeshwar Bachhav, Wilfried Schwab, Alexander Birkmann, Kurt Voegtli
  • Patent number: 10945998
    Abstract: A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: March 16, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Sanford Markowitz, Stanton Gerson, Amar Desai, Won Jin Ho
  • Patent number: 10940143
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: March 9, 2021
    Assignee: Poxel SA
    Inventor: Anthony W. Czarnik
  • Patent number: 10844126
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: November 24, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Patent number: 10588909
    Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: March 17, 2020
    Assignees: Taivex Therapeutics Corporation, Development Center For Biotechnology
    Inventors: Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau
  • Patent number: 10576071
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 3, 2020
    Assignee: Poxel SA
    Inventor: Anthony W. Czarnik
  • Patent number: 10512622
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 24, 2019
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Patent number: 10376518
    Abstract: The present invention provides a method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates T-cell receptor (TCR) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject. The invention also provides compositions and kits for use in such methods.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 13, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Shawn Ellis, Clare Notley, Michael Ehrenstein
  • Patent number: 10251852
    Abstract: Disclosed are compositions and methods for treating a condition characterized by a dysregulation in macrophage lipid homeostasis. The disclosed methods may include the administration of an agent selected from a PPAR? agonist, a LXR agonist, or a combination thereof. In certain aspects, the disclosed methods may be used to prevent, treat, or ameliorate conditions such as pulmonary alveolar proteinosis (PAP) and/or symptoms associated therewith.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: April 9, 2019
    Assignee: Children's Hospital Medical Center
    Inventors: Bruce Trapnell, Tony Sallese, Brenna Carey, Takuji Suzuki
  • Patent number: 10227360
    Abstract: The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of a compound of formula (I) for the treatment of metabolic disorders, particularly Type 2 diabetes and associated diseases.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 12, 2019
    Assignee: Piramal Enterprises Limited
    Inventors: Sanjay Kumar, Rajiv Sharma, Somnath Halder, Sangameshwar Prabhakar Sawargave, Vijaykumar Bhagwan Deore
  • Patent number: 10183015
    Abstract: This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 22, 2019
    Assignee: Medivation Technologies LLC
    Inventors: Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha
  • Patent number: 10172837
    Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: January 8, 2019
    Assignee: Naia Metabolic, Inc.
    Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
  • Patent number: 10034868
    Abstract: The present invention relates to the prevention and the treatment of rapidly progressive glomerulonephritis.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: July 31, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS DESCARTES
    Inventors: Pierre-Louis Tharaux, Carole Henique Greciet, Guillaume Bollee
  • Patent number: 9925175
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: March 27, 2018
    Assignee: DeuteRx, LLC
    Inventor: Anthony W. Czarnik
  • Patent number: 9782395
    Abstract: The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy) benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 10, 2017
    Assignee: MINORYX THERAPEUTICS S.L.
    Inventors: Ana María García Collazo, David John Augustus Eckland, Maria Pilar Pizcueta Lalanza, Marc Martinell Pedemonte
  • Patent number: 9701638
    Abstract: The invention provides compounds of formula (I) and salts thereof wherein R4-R8 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: July 11, 2017
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. Lavoie, Joseph David Bauman, Hye Yeon Sagong, Eddy Arnold, Ajit Parhi, Kalyan Das, Suyambu Kesava Vijayan, Disha Patel
  • Patent number: 9701675
    Abstract: Provided are methods of treating and/or preventing dermatological disorders. Provided are methods of reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPV4 inhibitor. Further provided are compositions including a TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application. Further provided is a transgenic mouse whose genome includes deletions of the Trpv4 gene in keratinocytes of the epidermis, wherein said transgenic mouse is a knockout for the Trpv4 gene in keratinocytes of the epidermis following keratinocyte-specific activation and expression of a site-specific recombination enzyme.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: July 11, 2017
    Assignees: Duke University, The Regents of the University of California
    Inventors: Wolfgang Liedtke, Martin Steinhoff, Farshid Guilak
  • Patent number: 9670197
    Abstract: Certain embodiments of the present invention provide selected compounds having a molecular structure according to Formula 1: In Formula 1, Z is —CO—, —SO—, or —SO2—; Ar is phenyl, heteroaryl, or heterocycloalkyl; Het is heteroaryl; R is R?, X, or NR1R2; R? is R3, or OR3; R? is R4, or OR4; R1 and R2 are each independently H, alkyl, or acyl; R3 is H, heteroaryl, or alkyl; R4 is H, heteroaryl, or CnH2n+1 (n>2); and X is F, Br, I, CN, or NO2. In some embodiments, compounds having a molecular structure according to Formula 1 have the property of inhibiting a growth of a cell line selected from HeLa and MB468 with a sub-micromolar IC50.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 6, 2017
    Assignee: The Regents of the University of California
    Inventors: Wen-Hwa Lee, Jiewen Zhu, Chun-Mei Hu
  • Patent number: 9643963
    Abstract: The invention relates to 1,2,4-thiadiazole derivatives and their use to treat parasites.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: May 9, 2017
    Assignee: Avista Pharma Solutions, Inc.
    Inventors: Hao Liu, Jessica Marie Sligar, Jason Daniel Speake, Joseph A. Moore, III, Brent Christopher Beck
  • Patent number: 9592225
    Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: March 14, 2017
    Assignee: AICURIS ANTI-INFECTIVE CURES GMBH
    Inventors: Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
  • Patent number: 9566269
    Abstract: Modified release pharmaceutical compositions of epalrestat are provided. Methods of manufacturing the tablets and treating various diseases and conditions, including diabetes and diabetic complications, by administering the modified release compositions to patients in need thereof are also provided.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: February 14, 2017
    Assignee: Bionevia Pharmaceuticals Inc.
    Inventors: Isabel Kalofonos, Judy Caron, William Martin-Doyle
  • Patent number: 9550764
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, hydrates and solvates thereof for use in the treatment of cancer:
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: January 24, 2017
    Assignee: The Institute of Cancer Research: Royal Cancer Hospital
    Inventors: Keith Jones, Matthew David Cheeseman, Spyridon Linardopoulos, Amir Faisal, Olivier Remi Barbeau, Andrew Kalusa
  • Patent number: 9527838
    Abstract: Novel pyridine-2-carboxamide derivatives of formula I and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: December 27, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Emma R. Parmee, Jiayi Xu
  • Patent number: 9499503
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: November 22, 2016
    Assignee: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen R. Laird, John Robinson, Shelley Allen
  • Patent number: 9447033
    Abstract: The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein X1, R1, R2, R3, R4, and R5 are defined as set forth in the specification. The compounds are useful as potassium ion channel inhibitors.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: September 20, 2016
    Assignee: Japan Tobacco Inc.
    Inventors: Mushtaq Mulla, Derek Edward John, Richard John Hamlyn, Sasha Louise Garrett, Basil Hartzoulakis, David Madge, John Ford
  • Patent number: 9409902
    Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: August 9, 2016
    Assignee: Taivex Therapeutics Corporation
    Inventors: Johnson Lau, Jiann-Jyh Huang
  • Patent number: 9346770
    Abstract: Phenyl propanoic acid compounds having activating effect on peroxisome proliferator-activated receptors (PPAR?,?,?) and a preparation method and uses thereof are provided in the present invention. The compounds can be used for treating or preventing diseases associated with peroxisome proliferator-activated receptors (PPAR?,?,?).
    Type: Grant
    Filed: June 18, 2011
    Date of Patent: May 24, 2016
    Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Yaping Wang, Guojun Zheng, Peng Sun, Yi Li, Yingqiu Wu, Bin Liu, Xiaoyu Liu, Hua Bai, Hongyan Li, Xiaohe Zheng
  • Patent number: 9339543
    Abstract: Pharmaceutical formulations comprising solid pharmaceutically acceptable organic acids, such as maleic acid or tartaric acid, that inhibit the disproportionation of pharmaceutically acceptable acid salts of active pharmaceutical ingredients, and methods of manufacturing such pharmaceutical compositions. The pharmaceutically acceptable acid salt of the active pharmaceutical ingredient has a pKa of less than about 6.0, and wherein the solid pharmaceutically acceptable organic acid has a pKa of less than about 4.0 and an aqueous solubility in the range of about 500 to about 2000 milligrams per milliliter. A pharmaceutical formulation comprising a pharmaceutical acceptable acid salt of pioglitazone, a solid pharmaceutically acceptable organic acid selected from the group consisting of maleic acid or tartaric acid, and an excipient that promotes disproportionation, wherein the ratio by weight of the solid pharmaceutically acceptable organic acid to excipient is from about 1:6 to about 1:1.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: May 17, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher T. John, Paul A. Harmon
  • Patent number: 9301952
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: April 5, 2016
    Assignee: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Patent number: 9212179
    Abstract: The present invention relates to the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. Also provided are methods for the treatment and/or prevention of one or more metabolic disorders, for example, obesity or diabetes, utilizing fatostatin A and/or a derivative and/or analog thereof and/or the A-B-C tripartite compounds.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: December 15, 2015
    Assignee: Baylor College of Medicine
    Inventors: Motonari Uesugi, Salih J. Wakil, Lutfi Abu-Elheiga, Mizuki Watanabe
  • Patent number: 9192603
    Abstract: Heterocyclic sulfone compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: November 24, 2015
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Corey R. Hopkins, Colleen M. Niswender, Rocco D. Gogliotti, James M. Salovich, Darren W. Engers, Yiu-Yin Cheung
  • Patent number: 9126992
    Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: September 8, 2015
    Assignee: Romark Laboratories, L.C.
    Inventors: Jean-Francois Rossignol, J. Edward Semple
  • Patent number: 9102666
    Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: August 11, 2015
    Assignees: ZINFANDEL PHARMACEUTICALS, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Allen D. Roses, Rajneesh Taneja
  • Patent number: 9040704
    Abstract: Herein are disclosed fluorescent dyes based around a framework for a ligand comprising a pyridyl group linked to a diaryl anilido unit. A variety of ligands based on this framework are disclosed. The ligands chelate to a BF2 center to produce the fluorescent dye. The disclosed dyes combine longer Stokes shifts (approximately 100 nm) with increased quantum yields. They are also photostable in aqueous and organic solutions for several hours. These dyes may be used in the labeling of biomolecules for bioimaging and assays. Also disclosed are methods for the synthesis of these dyes.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: May 26, 2015
    Assignee: UTI LIMITED PARTNERSHIP
    Inventors: Warren Edward Piers, Juan Felipe Araneda
  • Publication number: 20150141428
    Abstract: The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Shawn J. Stachel, Melissa Egbertson, Edward Brnardic, Kristen G. Jones, John M. Sanders, Darrell Henze
  • Publication number: 20150141433
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 21, 2015
    Inventors: David R. Anderson, Robert A. Volkmann
  • Patent number: 9034871
    Abstract: The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(?O)OH, -L-CH?CHC(?O)OH, -L-C(?O)NH2, -L-C(?O)NH(C1-3 alkyl), -L-C(?O)N(C1-3 alkyl)2, -L-S(?O)2(C1-3alkyl), -L-S(?O)2NH2, -L-S(?O)2N(C1-3 alkyl)2, -L-S(?O)2NH(C1-3 alkyl), -L-C(?O)NHOH, -L-C(?O)CH2NH2, -L-C(?O)CH2OH, -L-C(?O)CH2SH, -L-C(?O)NHCN, -L-NHC(?O)ORo, -L-C(?O)NHRo, -L-NH(C?O)NHRo, -L-C(?O)N(Ro)2, -L-NH(C?O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: May 19, 2015
    Inventors: Rachel Slade, Yevgeniya Klimova, Robert J. Halter, Ashantai J. Yungai, Warren S. Weiner, Ruth J. Walton, Jon Adam Willardsen, Mark B. Anderson, Kenton Zavitz
  • Publication number: 20150133473
    Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 20, 2013
    Publication date: May 14, 2015
    Applicant: NOVARTIS AG
    Inventors: Matthew Burger, Joseph E. Drumm III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
  • Publication number: 20150133364
    Abstract: The present application relates to prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventors: Hans-Georg LERCHEN, Ursula KRENZ, Jörg KELDENICH, Nicole DIEDRICHS, Thomas KRAHN, Claudia HIRTH-DIETRICH, Barbara ALBRECHT-KÜPPER
  • Publication number: 20150133507
    Abstract: The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.
    Type: Application
    Filed: December 10, 2012
    Publication date: May 14, 2015
    Applicant: ARES TRADING S.A.
    Inventor: Bjoern Colin Kahrs
  • Patent number: 9029293
    Abstract: An inhibitor for tobacco axillary bud growth, the inhibitor containing one or more cell division inhibitors selected from pyridine-based compounds and benzamide-based compounds. This inhibitor may further include an aliphatic alcohol having 6 to 20 carbon atoms in combination with the one or more cell division inhibitors.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: May 12, 2015
    Assignee: SDS Biotech K.K.
    Inventors: Motoki Tanaka, Keijitsu Tanaka, Takeshi Shibuya, Eiji Ikuta, Kotaro Yoshinaga, Yuki Yamaguchi
  • Publication number: 20150126485
    Abstract: The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 7, 2015
    Applicant: Novartis AG
    Inventors: Pascal Furet, Robert Martin Grotzfeld, Wolfgang Jahnke, Darryl Brynley Jones, Paul William Manley, Andreas Marzinzik, Xavier Francois Andre Pelle, Bahaa Salem, Joseph Schoepfer
  • Publication number: 20150126522
    Abstract: This invention relates to novel substituted benzamides according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 7, 2015
    Applicant: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Celine Duquenne, Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Sharad Kumar Verma
  • Publication number: 20150111741
    Abstract: A pesticidal composition comprises a synergistically effective amount of a nicotinic acetylcholine receptor (nAChR) agonist compound and a pesticide selected from N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)thio)propanamide (I), N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)sulfinyl)propanamide (II), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests. A method of protecting a plant from infestation and attack by insects comprises contacting the plant with the synergistic pesticidal composition.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Luis E. Gomez, Mike Shaw, Tony K. Trullinger, Ricky Hunter, John Herbert, Mary E. Kubiszak
  • Publication number: 20150111730
    Abstract: A pesticidal composition comprises a compound of formula I or any agriculturally acceptable salt thereof, wherein R1, R2, R4, R5, R6, R7, Z, Q, and Y are as described herein. A method of controlling pests comprises applying the pesticidal composition near a population of pests, or to an area to control pests.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Noormohamed M. Niyaz, Ann M. Buysse, David A. Demeter, Negar Garizi, Ricky Hunter, Daniel Knueppel, Paul R. LePlae, Christian T. Lowe, Akshay Patny, Tony K. Trullinger, Martin J. Walsh, Yu Zhang
  • Publication number: 20150111927
    Abstract: The present invention relates to selective cancer treatment regimes based on assaying for the presence or absence of a glutamine or a nucleic acid that encodes glutamine at position 859 of the catalytic p110? subunit of PI3K; methods for producing a transmittable form of information for predicting the responsiveness of patient to (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof; and a kit thereof.
    Type: Application
    Filed: March 27, 2013
    Publication date: April 23, 2015
    Inventors: Pascal Furet, Christine Fritsch, Sauveur-Michel Maira
  • Publication number: 20150111900
    Abstract: The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.
    Type: Application
    Filed: May 1, 2013
    Publication date: April 23, 2015
    Inventors: Nageswara Rao Irlapati, Zubair Abdul Wajid Shaikh, Vijay Pandurang Karche, Gokul Keruji Deshmukh, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20150111865
    Abstract: An object of the present invention is to provide a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I): (wherein all symbols represent the same meanings as described in the specification), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 23, 2015
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Masahiro Ikura, Masato Higashino, Maki Iwahashi, Kazuya Hashimura
  • Patent number: RE46724
    Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: February 20, 2018
    Assignee: Romark Laboratories, L.C.
    Inventors: Jean-Francois Rossignol, J. Edward Semple
  • Patent number: RE47786
    Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: December 31, 2019
    Assignee: Romark Laboratories L.C.
    Inventors: Jean-Francois Rossignol, J. Edward Semple